In the next stage, we analyzed patients with breast cancer, characterized as hormone receptor (HR) positive and HER2 positive (HR+HER2+), HR positive and HER2 negative (HR+HER2-), and HR negative, HER2 negative (triple negative, TNBC). This evidence concerns the gene NR4A1 and breast carcinoma.